GLP1R and diabetic kidney disease: Furthermore, DIRECT demonstrated the cardio-metabolic benefit of metformin (178), BEAT-DKD supported the clinical efficacy of SGLT2 inhibitors and GLP1R agonists in diabetic patients with DKD (179, 180), and StemBANCC established four different stem cell-based replacement treatments (181–183).